Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered a return of 116.15% over the past year. Since KNSA does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Kiniksa Pharmaceuticals, Ltd. one year ago would be worth $21,615 today, representing a gain of $11,615.

Kiniksa Pharmaceuticals, Ltd. (KNSA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For KNSA, the total return equals the price-only return.

Yes, Kiniksa Pharmaceuticals, Ltd. (KNSA) outperformed the S&P 500 by 84.82 percentage points over the past year. KNSA delivered a total return of 116.15%, compared to the S&P 500's 31.32%. This 84.82pp alpha means investors in KNSA earned more than a passive S&P 500 index fund.

Kiniksa Pharmaceuticals, Ltd. (KNSA) experienced a maximum drawdown of -14.33% over the past year, declining from its peak on 2026-04-06 to its trough on 2026-04-21. The stock recovered to its prior peak by 2026-04-28. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Kiniksa Pharmaceuticals, Ltd. (KNSA)'s long-term returns with dividends reinvested. Over 10 years, the total return is 199.1% (11.6% CAGR) — $10,000 would have grown to $29,908. Over 20 years: 199.1% total return (5.6% CAGR) — $10,000 → $29,907. Over 30 years: 199.1% total return (3.7% CAGR) — $10,000 → $29,907. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Kiniksa Pharmaceuticals, Ltd.'s best calendar year was 2025 with a total return of 106.9%. Its worst year was 2019 with a total return of -58.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 165.3 percentage points.